Back to list

Adolescence Astellas

University of North Carolina at Chapel Hill


The primary objective of this study is to evaluate the safety and tolerability of an investigational vaccine to prevent allergic reactions in adolescent subjects with peanut allergy.


Allergy, Pediatrics


Drug or Biologic



12 - 17 years


Study Population

Adolscence subjects between ages 12 and 17 who have a history of peanut allergy.


Edwin Kim
Clinical Associate Professor
Medicine-UNCP A Allergy and Immunology

For questions, contact:

Deanna Hamilton
(919) 259-4729

Recruitment Period End

January 31, 2020


Primary Location
Clinical & Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 12 - 17 years

Participant qualification(s) Subject must have: • A history of peanut allergy documented by blood work and skin testing • No history of severe (needing help breathing or maintain blood pressure) allergic reaction • No other medical diagnosis that may make participation dangerous.

Not eligible if: Subjects cannot: • Have a history of severe asthma (may have a history of mild asthma) • Cannot be pregnant or could become pregnant during the study • Be taking certain medication, which could interact with the study vaccine.

Number of Visits

    » 13 In person visit(s)

    1 screening visit, 2 food challenges, 4 vaccine injection visits, 4 follow up visits

    » 4 Remote visit(s)

    Phone calls to check on symptoms the day after vaccine injections.

Participation Period

9 months


$100 for each study visit, $200 for each food challenge visit.

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.